23.01.2020 HumanOptics AG  DE000A1MMCR6

DGAP-News: HumanOptics AG: Artificial iris from HumanOptics receives US health insurance approval


DGAP-News: HumanOptics AG / Key word(s): Miscellaneous
HumanOptics AG: Artificial iris from HumanOptics receives US health insurance approval

23.01.2020 / 11:00
The issuer is solely responsible for the content of this announcement.

Artificial iris from HumanOptics receives US health insurance approval

Important step towards expanding market position

Erlangen, 23 January 2020 - HumanOptics AG has received health insurance approval for its artificial iris CUSTOMFLEX(R) ArtificialIris in the USA. The specialist for high-quality eye surgery implants is thus further improving its position in this important market. Approval by the state Center for Medicare and Medicaid Services (CMS) as a reimbursable medical product ensures that costs are covered by health insurance and is an important prerequisite for patients to decide in favor of treatment.

With CUSTOMFLEX(R) ArtificialIris, HumanOptics is currently the only company whose artificial iris has been approved for the US market by the FDA, and thus already has an important unique selling point. As a result of the additional health insurance approval now granted retroactively to January 1, 2020, significantly more patients in the USA will in future have access to this unique therapy.

CUSTOMFLEX(R) ArtificialIris is used for patients who have partially or completely lost their iris due to an accident or who have no or uncomplete iris from birth. Such a defect is very stressful in everyday social life, leads to complaints such as severe light sensitivity or loss of vision and increases the risk of other eye diseases such as glaucoma and cataract. The high-quality implant replaces the completely or partially missing or damaged iris.

Each CUSTOMFLEX(R) ArtificialIris is individually manufactured by HumanOptics after the original appearance of the patient's iris. It consists of a flexible silicone material which is inserted into the eye in a well-tolerated manner by means of a small incision technique. This both medically and aesthetically high-quality restoration guarantees a very high degree of patient satisfaction.

Company profile:

HumanOptics AG (www.humanoptics.com) specialises in the development, production and sale of high-quality implants and accessories for eye surgery and stands for the highest quality and innovative strength in this segment. The most important products are intraocular lenses (IOL) for the treatment of cataracts and various forms of ametropia as well as artificial irises. In addition, the company offers the operating ophthalmologists accessories and complementary products as well as comprehensive consulting services. The shares of HumanOptics AG are listed on the Basic Board of the Frankfurt Stock Exchange.

Contact us:

HumanOptics AG
Investor Relations
Spardorfer Str. 150
91054 Erlangen
Telefon: +49 (0) 9131 50665-0
E-Mail: [email protected]

23.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: HumanOptics AG
Spardorfer Str. 150
91054 Erlangen
Phone: +49 (0)9131 - 50665-60
Fax: +49 (0)9131 - 50665-93
E-mail: [email protected]
Internet: www.humanoptics.de
ISIN: DE000A1MMCR6, DE000A255FK8
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart
EQS News ID: 959455

End of News DGAP News Service

959455  23.01.2020 


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 10,51 11,56 11,04 10,68 9,36 10,20 0,00
EBITDA1,2 0,82 0,54 -1,28 -1,27 -1,90 0,80 0,00
EBITDA-Marge3 7,80 4,67 -11,59 -11,89 -20,30 7,84 0,00
EBIT1,4 0,33 0,13 -1,71 -1,76 -2,42 0,34 0,00
EBIT-Marge5 3,14 1,12 -15,49 -16,48 -25,86 3,33 0,00
Jahresüberschuss1 0,16 0,03 -1,78 -1,89 -2,57 -0,25 0,00
Netto-Marge6 1,52 0,26 -16,12 -17,70 -27,46 -2,45 0,00
Cashflow1,7 0,99 0,53 -1,30 -1,84 -1,53 0,30 0,00
Ergebnis je Aktie8 0,05 0,01 -0,58 -0,60 -0,74 -0,07 0,29
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1MMCR 9,000 Halten 31,39
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,43 34,23 0,63 -57,33
12,06 - 3,35 -18,76
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
0,00 0,00 0,00 18.12.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 03.12.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,91% -6,25% 8,43% 7,14%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HumanOptics AG  ISIN: DE000A1MMCR6 können Sie bei DGAP abrufen

Medtech , A1MMCR , H9O1 , FWB:H9O1